Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.

Andrea Alonci,Alessandro Allegra,Sabina Russo,Giuseppa Penna,Giacomo Bellomo,Arianna D’Angelo,Salvatore Campo,Antonino Cannavò,Raffaella Centorrino,Caterina Musolino

Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.

2012

Andrea Alonci
Alessandro Allegra
Sabina Russo
Giuseppa Penna
Giacomo Bellomo
Arianna D’Angelo
Salvatore Campo
Antonino Cannavò
Raffaella Centorrino
Caterina Musolino

The aim of the present study was to determine serum levels of neutrophil gelatinase-associated lipocalin (NGAL) and leptin in patients with chronic myeloid leukemia (CML) at diagnosis and after imatin

Keywords:

Diabetes mellitus
Immunology
Medicine
Lipocalin
Myeloid leukemia
Mesylate
Leptin
Neutrophil gelatinase-associated lipocalin
Imatinib
imatinib mesylate
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations